Regeneron Pharmaceuticals, Inc. has signed an important deal with Sanofi worth up to $8 billion.

Oct 6, 2026, 7:56 AM ETDealRead the original at SEC EDGAR

Good for REGN

Regeneron receives $1.0 billion upfront and may earn up to $7.0 billion more, plus half the profits from 4 new antibody medicines. It shares development costs, may cover spending above a budget cap, and expects a third-quarter charge to cut profit per share by $0.18, but the deal's cash and product opportunity favor the company.

REGN · Regeneron Pharmaceuticals, Inc.

AI read · Good for REGN

The AI's read

The payment and chance to share income from new medicines give Regeneron more resources and future income opportunities. Regeneron must share development costs and may pay spending above the budget cap, though it may recover some of that spending later. Sanofi leads sales, and a third-quarter charge will also lower profit per share. The deal's cash and product opportunities still favor Regeneron.

Get alerts for REGN

Follow Regeneron Pharmaceuticals, Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for REGN

Free on the App Store and Google Play, or on the web.